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Purpose: To report a case of bilateral primary intraocular lymphoma.
Case report: A 33-year-old man presented with bilateral blurred vision since two 
years ago. Examination revealed large keratic precipitates, anterior chamber reaction, 
posterior subcapsular cataracts, and vitreous infiltration. After a short trial of topical 
and periocular steroids, diagnostic 25-gauge pars plana vitrectomy was performed and 
cytologic evaluation of the aspirate confirmed a diagnosis of intraocular lymphoma. 
The patient was subsequently managed with intravitreal methotrexate in both eyes and 
responded favorably. Central nervous system workup for lymphoma was negative.
Conclusion: Primary intraocular lymphoma should be considered in young adults 
suffering from chronic recalcitrant panuveitis.
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INTRODUCTION
Malignant lymphomas are categorized into 
Hodgkin and non-Hodgkin lymphomas 
(NHL). Although most NHLs (80%) arise 
from B-lymphocytes and their precursor cells, 
non-Hodgkin lymphomas originating from 
T-lymphocytes (14%) and natural killer cells 
(6%) have also been well-recognized. Primary 
central nervous system lymphoma (PCNSL) may 
arise from the brain, spinal cord, meninges or 
eyes. PCNSL constitutes 1-2% of all lymphomas 
and 5% of all primary CNS tumors.1 Primary 
intraocular lymphoma (PIOL) is an uncommon 
subset of PCNSL which involves the retina, 
vitreous or optic nerve head.2,3 PIOL typically 
affects elderly patients at a mean age of 60 years 
and rarely occurs in young children.1 Herein, 
we report a young patient with bilateral PIOL 
masquerading as panuveitis for a couple of 
years.
CASe RePORT
A 33-year-old Caucasian male with no 
significant past medical history, was referred 
to our center in June 2010 with refractory 
bilateral panuveitis of 2 years’ duration. He 
was being treated with fluorometholone 0.1% 
drops every 6 hours, tropicamide 1% every 8 
hours and prednisolone 50 mg per day. Best 
corrected visual acuity (BCVA) was counting 
fingers at 30cm (20/3200) in both eyes. Slit lamp 
examination revealed multiple large keratic 
precipitates (KPs) and deep anterior chamber 
with +1 cell reaction in both eyes. There was 
mild posterior subcapsular (PSC) cataract in the 
right eye but the crystalline lens was clear in 
the left eye. There were 2+ cells in the anterior 
vitreous in both eyes. Intraocular pressure 
(IOP) was 15 mmHg and 13 mmHg in the right 
and left eyes, respectively. Due to hazy media, 
details were not visible but the retina seemed Intraocular Lymphoma; Karimi
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attached. Systemic and laboratory evaluations 
for uveitis including complete blood count 
(CBC), erythrocyte sedimentation rate (ESR), 
C-reactive protein (CRP), tuberculin skin test 
(PPD), angiotensin converting enzyme (ACE), 
urine analysis, chest X-ray, HLA-B5, HLA-B51 
and HLA-B27 which had been done at another 
center were negative. Preliminary diagnosis was 
panuveitis suspecting a masquerade syndrome. 
Trans-septal triamcinolone acetonide was 
injected in the right eye and five days later 
diagnostic 25-gauge pars plana vitrectomy 
and intravitreal triamcinolone acetate (2 mg) 
injection was performed in his left eye. Ten 
days later pars plana vitrectomy and intravitreal 
injection of methotrexate (400microgram/0.1ml) 
was performed in the right eye; at the 
same session, intravitreal methotrexate was 
also injected in the left eye. Diluted and 
undiluted vitreous samples were processed 
for cytopathology. Cytospin and cytoblock 
preparations of specimens from the right eye 
disclosed a heterogenous infiltration of cells, 
some with medium to large hyperchromatic 
nuclei and scattered ghost cells (Figures 1A 
and 1B). Most of the cells were lost during 
immunocytochemistry but still a few large 
cells which were immunoreactive for CD20 
were present (Figure 1C). These cytopathologic 
features in the right eye were suggestive of 
intraocular B-cell lymphoma. Cytopathologic 
examination of specimens from the left vitreous 
revealed a heterogenous infiltration of lymphoid 
cells among which clusters of medium to 
large cells with hyperchromatic nuclei were 
observed (Figure 1D). The cells were strongly 
immunoreactive for CD20 (Figure 1E) but not for 
CD3 (Figure 1F). CD3 is a cell marker specific 
for T-lymphocytes and since PIOL originates 
mainly from B-cells, a positive immune reaction 
for CD3 is not seen in PIOL. The cytopathologic 
findings in left eye were also suggestive of 
intraocular B-cell lymphoma and supported 
the previous cytopathologic diagnosis in the 
fellow eye.
Neuroimaging studies and neurological 
consultation was performed. Brain and spinal 
cord MRI was negative for lymphoma. During 
15 months of follow up, the patient received 
two injections of intravitreal methotrexate 
(400microgram/0.1ml) in his right eye, 3 and 
5 months and one in his left eye, 4 months 
after surgery. At final examination, BCVA was 
improved to 4/10 and 3/10 in the right and left 
eyes respectively and intraocular inflammation 
was well controlled.
DISCUSSION
Many patients with the intraocular variant of 
Figure 1. Cytopathologic features of the right vitreous 
sample: (A) Note the heterogenous lymphoid infiltration, 
some with medium to large hyperchromatic nuclei 
(Hematoxylin & Eosin, ×1000). (B) A moderately large-
sized mononuclear cell (arrow) with hyperchromatic 
and irregular nucleus (Hematoxylin & Eosin, ×1000) 
and (C) a few large cells with strong immune reactivity 
for CD20 (×1000).  Cytopathologic findings in the left 
vitreous sample: (D) note the heterogenous infiltration of 
lymphoid cells (Hematoxylin & Eosin, ×400) composed 
of clusters of medium to large-sized cells (arrow in small 
box on the upper right side) with hyperchromatic nuclei. 
(e) Note strong immune reactivity of the atypical cells 
for CD20 (×1000). (F) Lack of immune reactivity for CD3 
(×1000).
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PCNSL are initially misdiagnosed as having 
uveitis. The patient described herein had PIOL 
masquerading as panuveitis for 2 years. In 
a series of 32 histologically proven cases of 
PIOL, the average interval between the onset 
of ocular symptoms and histological diagnosis 
was 21 months.1 Although PIOL usually affects 
elderly patients, it should be considered in any 
patient with chronic uveitis. As an example 
in 1994, two young patients with intraocular 
lymphoma presented with retinal vasculitis.4 
Intraocular lymphoma generally occurs at a 
younger age in HIV-positive subjects.5 As a 
result of the varied clinical features and rarity 
of the condition, a high index of suspicious 
is required for the diagnosis of PIOL. Early 
diagnosis is important since it enables rapid 
initiation of treatment, may reduce morbidity 
and improve the prognosis. 
It is difficult to arrive at a histopathological 
diagnosis of PIOL,6-8 thus research has been 
focused on developing other methods to assist 
the diagnosis of this condition. These include 
immunohistochemistry, flow cytometry, 
molecular analysis, cytokine level analysis, and 
polymerase chain reaction based methods.9-11 
The actual incidence PIOL is unknown. The 
incidence of PCNSL has increased in both 
immunocompetent and immunocompromised 
subjects from 0.027/100,000 in 1973 to 1/100,000 
in the early 90s.12 The underlying cause for 
the increase in immunocompetent patients is 
unknown.13
Characteristically, PIOL causes bilateral 
involvement in up to 80% of cases. Ocular 
involvement may precede, occur simultaneously 
or follow CNS disease. More than 50% of 
PCNSL cases present with ophthalmic findings. 
The most common manifestations of PIOL are 
isolated posterior uveitis or vitritis (50% of 
cases), combined anterior and posterior uveitis 
(22% of cases) and choroiditis, chorioretinitis 
or subretinal pigment epithelial infiltrates.1 A 
histological diagnosis should be established by 
performing cytologic examination of vitreous 
samples obtained by pars plana vitrectomy.
Most patients with ocular NHL die within 
2 years of diagnosis as a result of progressive 
or recurrent CNS disease. Previous reports 
suggested that approximately 80% of patients 
with PIOL will subsequently develop brain 
lymphoma.6,7
AIDS-related immunosuppression and 
congenital or iatrogenic immunodeficiencies 
are risk factors for NHL. However, no clear 
risk factors have been identified for PCNSL 
in immunocompetent individuals. In our 
patient the presence of refractory uveitis for 
two years, negative laboratory tests and a 
high index of suspicious prompted diagnostic 
vitrectomy. If vitreous biopsy is unable to 
establish the diagnosis, biopsy of retinal and 
choroidal lesions can be performed; this is 
a potentially hazardous intervention which 
can be achieved by a variety of external and 
internal approaches.14 This, however, should be 
considered as the investigation of last resort. 
Biopsy samples should be taken only after 
consultation with histologists, microbiologists 
and molecular biologists to obtain advice on 
tissue handling, culture and fixation methods.
Ever since the first description of intraocular 
(non-Hodgkin) lymphoma as ocular reticulum 
cell sarcoma in 1951,15 its treatment has evolved 
from enucleation16 to radiation therapy alone 
or in combination with chemotherapy, systemic 
and intravitreal chemotherapy, and more 
recently to biological therapy. The optimal 
goal of treatment for vitreoretinal lymphoma is 
eradication of intraocular disease on one hand 
and prevention of CNS or systemic relapse, 
on the other. The most efficacious therapy has 
not yet been identified and reports are limited 
to small case series. The drug of choice for 
intravitreal chemotherapy may be methotrexate 
(400 μg). In order to overcome the side effects 
and reduce the frequency of intravitreal 
injections of methotrexate and also to effectively 
deal with intraocular lymphomas resistant to 
methotrexate therapy, intravitreal injections 
of rituximab (1mg/0.1ml) for treatment of 
vitreoretinal lymphoma has been introduced.
Rituximab is a mouse/human chimeric 
immunoglobulin G1-K monoclonal antibody that 
targets the CD20 antigen present on the surface 
of malignant and normal B-lymphocytes, and 
received FDA approval in 1997 for systemic 
use in patients with follicular non-Hodgkin Intraocular Lymphoma; Karimi
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lymphoma and diffuse large B-cell lymphoma. 
It has also been used for other types of B-cell 
lymphoma. Since the vast majority of PIOLs 
and PCNSLs are B-cell in origin and express the 
CD20 antigen,17,18 rituximab is an ideal drug for 
intraocular and intrathecal adjuvant therapy.
In recent years, researchers have investigated 
innovative methods for treatment of intraocular 
lymphoma in animal models. Gregory and 
associates19 studied a novel treatment for 
intraocular lymphoma using membrane Fas 
ligand vesicles, the membrane-only form of 
Fas ligand, to activate innate immunity and 
terminate the immune privilege of the eye.
In summary this case report reveals that 
PIOL may occur in young adults and making 
an early diagnosis may save the patient’s sight.
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